Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography
A noteworthy proportion of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis. This was a...
Gespeichert in:
| Veröffentlicht in: | Clinical gastroenterology and hepatology 2024-11 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Clinical gastroenterology and hepatology |
| container_volume | |
| creator | Marti-Aguado, David Carot-Sierra, José Miguel Villalba-Ortiz, Aida Siddiqi, Harris Vallejo-Vigo, Rose Marie Lara-Romero, Carmen Martín-Fernández, Marta Fernández-Patón, Matías Alfaro-Cervello, Clara Crespo, Ana Coello, Elena Merino-Murgui, Víctor Madamba, Egbert Benlloch, Salvador Pérez-Rojas, Judith Puglia, Víctor Ferrández, Antonio Aguilera, Victoria Monton, Cristina Escudero-García, Desamparados Lluch, Paloma Aller, Rocío Loomba, Rohit Romero-Gomez, Manuel Marti-Bonmati, Luis |
| description | A noteworthy proportion of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis.
This was a real-world prospective study including a large dataset of MASLD patients with paired VCTE and liver biopsy from 6 centers. A total of 1196 patients were recruited and divided in training (3 centers, Spain), internal validation (2 centers, Spain), and external validation (1 center, United States) cohorts. In patients with indeterminate liver stiffness measurement (LSM) (8–12 kPa), a diagnostic algorithm was developed to identify significant fibrosis, defined as histological stage ≥F2. Statistical analysis was performed using Gaussian mixture model (GMM) and k-means unsupervised clusterization.
From the eligible population, 33%, 29%, and 31% had indeterminate VCTE in the training, internal and external validation samples, respectively. The controlled attenuation parameter allowed the differentiation of GMM clusters with a cutoff of 280 dB/m (area under the curve, 0.89; 95% confidence interval, 0.86–0.97). Within patients with |
| doi_str_mv | 10.1016/j.cgh.2024.10.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3129681226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356524010371</els_id><sourcerecordid>3129681226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1934-b1a729ef7e7337decb60019b4e7e9dee63fe37541da8934bb0e4070dfbfb5533</originalsourceid><addsrcrecordid>eNp9kM1OGzEUha2KCijlAbqpZslmUv-OGbFCKbSRgrogokvLP9fE0cw42E4l3h6HpF12dX2t7xzpfgh9IXhGMOm-bWb2eT2jmPK6zzDhH9A5EZy2UhJ-cnwz0Ykz9CnnDca05708RWesF4JQwc5RXDiYSvDB6hLi1ETfzPXkgtMFcuNjah5uH5ffm1UCXcaKNr9DWTeLyUGBNIapcs1TMOk93s7jVFIcBnA1oacc9om7QecSn5Perl8_o49eDxkuj_MCre7vVvOf7fLXj8X8dtla0jPeGqIl7cFLkIxJB9Z0GJPecJDQO4COeWBScOL0deWNwcCxxM4bb4Rg7AJdHWq3Kb7sIBc1hmxhGPQEcZcVI7TvrgmlXUXJAbUp5pzAq20Ko06vimC116w2qmpWe837r6q5Zr4e63dmBPcv8ddrBW4OANQb_wRIKtvqwoILCWxRLob_1L8B4DWPHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3129681226</pqid></control><display><type>article</type><title>Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography</title><source>Elsevier ScienceDirect Journals</source><creator>Marti-Aguado, David ; Carot-Sierra, José Miguel ; Villalba-Ortiz, Aida ; Siddiqi, Harris ; Vallejo-Vigo, Rose Marie ; Lara-Romero, Carmen ; Martín-Fernández, Marta ; Fernández-Patón, Matías ; Alfaro-Cervello, Clara ; Crespo, Ana ; Coello, Elena ; Merino-Murgui, Víctor ; Madamba, Egbert ; Benlloch, Salvador ; Pérez-Rojas, Judith ; Puglia, Víctor ; Ferrández, Antonio ; Aguilera, Victoria ; Monton, Cristina ; Escudero-García, Desamparados ; Lluch, Paloma ; Aller, Rocío ; Loomba, Rohit ; Romero-Gomez, Manuel ; Marti-Bonmati, Luis</creator><creatorcontrib>Marti-Aguado, David ; Carot-Sierra, José Miguel ; Villalba-Ortiz, Aida ; Siddiqi, Harris ; Vallejo-Vigo, Rose Marie ; Lara-Romero, Carmen ; Martín-Fernández, Marta ; Fernández-Patón, Matías ; Alfaro-Cervello, Clara ; Crespo, Ana ; Coello, Elena ; Merino-Murgui, Víctor ; Madamba, Egbert ; Benlloch, Salvador ; Pérez-Rojas, Judith ; Puglia, Víctor ; Ferrández, Antonio ; Aguilera, Victoria ; Monton, Cristina ; Escudero-García, Desamparados ; Lluch, Paloma ; Aller, Rocío ; Loomba, Rohit ; Romero-Gomez, Manuel ; Marti-Bonmati, Luis</creatorcontrib><description>A noteworthy proportion of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis.
This was a real-world prospective study including a large dataset of MASLD patients with paired VCTE and liver biopsy from 6 centers. A total of 1196 patients were recruited and divided in training (3 centers, Spain), internal validation (2 centers, Spain), and external validation (1 center, United States) cohorts. In patients with indeterminate liver stiffness measurement (LSM) (8–12 kPa), a diagnostic algorithm was developed to identify significant fibrosis, defined as histological stage ≥F2. Statistical analysis was performed using Gaussian mixture model (GMM) and k-means unsupervised clusterization.
From the eligible population, 33%, 29%, and 31% had indeterminate VCTE in the training, internal and external validation samples, respectively. The controlled attenuation parameter allowed the differentiation of GMM clusters with a cutoff of 280 dB/m (area under the curve, 0.89; 95% confidence interval, 0.86–0.97). Within patients with <280 dB/m, a LSM between 8.0–9.0 kPa showed a 93% sensitivity and a 91% negative predictive value to exclude significant fibrosis. Among patients with ≥280 dB/m, a LSM between 10.3 and 12.0 kPa diagnosed significant fibrosis with a 91% specificity. Applying this algorithm to the validation cohorts, 36% of the indeterminate VCTE were reallocated. The reallocated high-risk group showed a prevalence of 86% significant fibrosis, opening the therapeutic window for MASLD patients.
To identify candidates for MASLD treatment among indeterminate VCTE, an algorithm-based on the sequential combination of LSM and controlled attenuation parameter thresholds can optimize the diagnosis of moderate-to-advanced fibrosis.
[Display omitted]</description><identifier>ISSN: 1542-3565</identifier><identifier>ISSN: 1542-7714</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2024.10.014</identifier><identifier>PMID: 39551253</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Controlled Attenuation Parameter ; Liver Stiffness Measurement ; Metabolic Dysfunction–Associated Steatotic Liver Disease ; Significant Fibrosis</subject><ispartof>Clinical gastroenterology and hepatology, 2024-11</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1934-b1a729ef7e7337decb60019b4e7e9dee63fe37541da8934bb0e4070dfbfb5533</cites><orcidid>0000-0002-4266-6076</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1542356524010371$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39551253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marti-Aguado, David</creatorcontrib><creatorcontrib>Carot-Sierra, José Miguel</creatorcontrib><creatorcontrib>Villalba-Ortiz, Aida</creatorcontrib><creatorcontrib>Siddiqi, Harris</creatorcontrib><creatorcontrib>Vallejo-Vigo, Rose Marie</creatorcontrib><creatorcontrib>Lara-Romero, Carmen</creatorcontrib><creatorcontrib>Martín-Fernández, Marta</creatorcontrib><creatorcontrib>Fernández-Patón, Matías</creatorcontrib><creatorcontrib>Alfaro-Cervello, Clara</creatorcontrib><creatorcontrib>Crespo, Ana</creatorcontrib><creatorcontrib>Coello, Elena</creatorcontrib><creatorcontrib>Merino-Murgui, Víctor</creatorcontrib><creatorcontrib>Madamba, Egbert</creatorcontrib><creatorcontrib>Benlloch, Salvador</creatorcontrib><creatorcontrib>Pérez-Rojas, Judith</creatorcontrib><creatorcontrib>Puglia, Víctor</creatorcontrib><creatorcontrib>Ferrández, Antonio</creatorcontrib><creatorcontrib>Aguilera, Victoria</creatorcontrib><creatorcontrib>Monton, Cristina</creatorcontrib><creatorcontrib>Escudero-García, Desamparados</creatorcontrib><creatorcontrib>Lluch, Paloma</creatorcontrib><creatorcontrib>Aller, Rocío</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Romero-Gomez, Manuel</creatorcontrib><creatorcontrib>Marti-Bonmati, Luis</creatorcontrib><title>Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>A noteworthy proportion of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis.
This was a real-world prospective study including a large dataset of MASLD patients with paired VCTE and liver biopsy from 6 centers. A total of 1196 patients were recruited and divided in training (3 centers, Spain), internal validation (2 centers, Spain), and external validation (1 center, United States) cohorts. In patients with indeterminate liver stiffness measurement (LSM) (8–12 kPa), a diagnostic algorithm was developed to identify significant fibrosis, defined as histological stage ≥F2. Statistical analysis was performed using Gaussian mixture model (GMM) and k-means unsupervised clusterization.
From the eligible population, 33%, 29%, and 31% had indeterminate VCTE in the training, internal and external validation samples, respectively. The controlled attenuation parameter allowed the differentiation of GMM clusters with a cutoff of 280 dB/m (area under the curve, 0.89; 95% confidence interval, 0.86–0.97). Within patients with <280 dB/m, a LSM between 8.0–9.0 kPa showed a 93% sensitivity and a 91% negative predictive value to exclude significant fibrosis. Among patients with ≥280 dB/m, a LSM between 10.3 and 12.0 kPa diagnosed significant fibrosis with a 91% specificity. Applying this algorithm to the validation cohorts, 36% of the indeterminate VCTE were reallocated. The reallocated high-risk group showed a prevalence of 86% significant fibrosis, opening the therapeutic window for MASLD patients.
To identify candidates for MASLD treatment among indeterminate VCTE, an algorithm-based on the sequential combination of LSM and controlled attenuation parameter thresholds can optimize the diagnosis of moderate-to-advanced fibrosis.
[Display omitted]</description><subject>Controlled Attenuation Parameter</subject><subject>Liver Stiffness Measurement</subject><subject>Metabolic Dysfunction–Associated Steatotic Liver Disease</subject><subject>Significant Fibrosis</subject><issn>1542-3565</issn><issn>1542-7714</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OGzEUha2KCijlAbqpZslmUv-OGbFCKbSRgrogokvLP9fE0cw42E4l3h6HpF12dX2t7xzpfgh9IXhGMOm-bWb2eT2jmPK6zzDhH9A5EZy2UhJ-cnwz0Ykz9CnnDca05708RWesF4JQwc5RXDiYSvDB6hLi1ETfzPXkgtMFcuNjah5uH5ffm1UCXcaKNr9DWTeLyUGBNIapcs1TMOk93s7jVFIcBnA1oacc9om7QecSn5Perl8_o49eDxkuj_MCre7vVvOf7fLXj8X8dtla0jPeGqIl7cFLkIxJB9Z0GJPecJDQO4COeWBScOL0deWNwcCxxM4bb4Rg7AJdHWq3Kb7sIBc1hmxhGPQEcZcVI7TvrgmlXUXJAbUp5pzAq20Ko06vimC116w2qmpWe837r6q5Zr4e63dmBPcv8ddrBW4OANQb_wRIKtvqwoILCWxRLob_1L8B4DWPHA</recordid><startdate>20241116</startdate><enddate>20241116</enddate><creator>Marti-Aguado, David</creator><creator>Carot-Sierra, José Miguel</creator><creator>Villalba-Ortiz, Aida</creator><creator>Siddiqi, Harris</creator><creator>Vallejo-Vigo, Rose Marie</creator><creator>Lara-Romero, Carmen</creator><creator>Martín-Fernández, Marta</creator><creator>Fernández-Patón, Matías</creator><creator>Alfaro-Cervello, Clara</creator><creator>Crespo, Ana</creator><creator>Coello, Elena</creator><creator>Merino-Murgui, Víctor</creator><creator>Madamba, Egbert</creator><creator>Benlloch, Salvador</creator><creator>Pérez-Rojas, Judith</creator><creator>Puglia, Víctor</creator><creator>Ferrández, Antonio</creator><creator>Aguilera, Victoria</creator><creator>Monton, Cristina</creator><creator>Escudero-García, Desamparados</creator><creator>Lluch, Paloma</creator><creator>Aller, Rocío</creator><creator>Loomba, Rohit</creator><creator>Romero-Gomez, Manuel</creator><creator>Marti-Bonmati, Luis</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4266-6076</orcidid></search><sort><creationdate>20241116</creationdate><title>Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography</title><author>Marti-Aguado, David ; Carot-Sierra, José Miguel ; Villalba-Ortiz, Aida ; Siddiqi, Harris ; Vallejo-Vigo, Rose Marie ; Lara-Romero, Carmen ; Martín-Fernández, Marta ; Fernández-Patón, Matías ; Alfaro-Cervello, Clara ; Crespo, Ana ; Coello, Elena ; Merino-Murgui, Víctor ; Madamba, Egbert ; Benlloch, Salvador ; Pérez-Rojas, Judith ; Puglia, Víctor ; Ferrández, Antonio ; Aguilera, Victoria ; Monton, Cristina ; Escudero-García, Desamparados ; Lluch, Paloma ; Aller, Rocío ; Loomba, Rohit ; Romero-Gomez, Manuel ; Marti-Bonmati, Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1934-b1a729ef7e7337decb60019b4e7e9dee63fe37541da8934bb0e4070dfbfb5533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Controlled Attenuation Parameter</topic><topic>Liver Stiffness Measurement</topic><topic>Metabolic Dysfunction–Associated Steatotic Liver Disease</topic><topic>Significant Fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marti-Aguado, David</creatorcontrib><creatorcontrib>Carot-Sierra, José Miguel</creatorcontrib><creatorcontrib>Villalba-Ortiz, Aida</creatorcontrib><creatorcontrib>Siddiqi, Harris</creatorcontrib><creatorcontrib>Vallejo-Vigo, Rose Marie</creatorcontrib><creatorcontrib>Lara-Romero, Carmen</creatorcontrib><creatorcontrib>Martín-Fernández, Marta</creatorcontrib><creatorcontrib>Fernández-Patón, Matías</creatorcontrib><creatorcontrib>Alfaro-Cervello, Clara</creatorcontrib><creatorcontrib>Crespo, Ana</creatorcontrib><creatorcontrib>Coello, Elena</creatorcontrib><creatorcontrib>Merino-Murgui, Víctor</creatorcontrib><creatorcontrib>Madamba, Egbert</creatorcontrib><creatorcontrib>Benlloch, Salvador</creatorcontrib><creatorcontrib>Pérez-Rojas, Judith</creatorcontrib><creatorcontrib>Puglia, Víctor</creatorcontrib><creatorcontrib>Ferrández, Antonio</creatorcontrib><creatorcontrib>Aguilera, Victoria</creatorcontrib><creatorcontrib>Monton, Cristina</creatorcontrib><creatorcontrib>Escudero-García, Desamparados</creatorcontrib><creatorcontrib>Lluch, Paloma</creatorcontrib><creatorcontrib>Aller, Rocío</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Romero-Gomez, Manuel</creatorcontrib><creatorcontrib>Marti-Bonmati, Luis</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marti-Aguado, David</au><au>Carot-Sierra, José Miguel</au><au>Villalba-Ortiz, Aida</au><au>Siddiqi, Harris</au><au>Vallejo-Vigo, Rose Marie</au><au>Lara-Romero, Carmen</au><au>Martín-Fernández, Marta</au><au>Fernández-Patón, Matías</au><au>Alfaro-Cervello, Clara</au><au>Crespo, Ana</au><au>Coello, Elena</au><au>Merino-Murgui, Víctor</au><au>Madamba, Egbert</au><au>Benlloch, Salvador</au><au>Pérez-Rojas, Judith</au><au>Puglia, Víctor</au><au>Ferrández, Antonio</au><au>Aguilera, Victoria</au><au>Monton, Cristina</au><au>Escudero-García, Desamparados</au><au>Lluch, Paloma</au><au>Aller, Rocío</au><au>Loomba, Rohit</au><au>Romero-Gomez, Manuel</au><au>Marti-Bonmati, Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2024-11-16</date><risdate>2024</risdate><issn>1542-3565</issn><issn>1542-7714</issn><eissn>1542-7714</eissn><abstract>A noteworthy proportion of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis.
This was a real-world prospective study including a large dataset of MASLD patients with paired VCTE and liver biopsy from 6 centers. A total of 1196 patients were recruited and divided in training (3 centers, Spain), internal validation (2 centers, Spain), and external validation (1 center, United States) cohorts. In patients with indeterminate liver stiffness measurement (LSM) (8–12 kPa), a diagnostic algorithm was developed to identify significant fibrosis, defined as histological stage ≥F2. Statistical analysis was performed using Gaussian mixture model (GMM) and k-means unsupervised clusterization.
From the eligible population, 33%, 29%, and 31% had indeterminate VCTE in the training, internal and external validation samples, respectively. The controlled attenuation parameter allowed the differentiation of GMM clusters with a cutoff of 280 dB/m (area under the curve, 0.89; 95% confidence interval, 0.86–0.97). Within patients with <280 dB/m, a LSM between 8.0–9.0 kPa showed a 93% sensitivity and a 91% negative predictive value to exclude significant fibrosis. Among patients with ≥280 dB/m, a LSM between 10.3 and 12.0 kPa diagnosed significant fibrosis with a 91% specificity. Applying this algorithm to the validation cohorts, 36% of the indeterminate VCTE were reallocated. The reallocated high-risk group showed a prevalence of 86% significant fibrosis, opening the therapeutic window for MASLD patients.
To identify candidates for MASLD treatment among indeterminate VCTE, an algorithm-based on the sequential combination of LSM and controlled attenuation parameter thresholds can optimize the diagnosis of moderate-to-advanced fibrosis.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39551253</pmid><doi>10.1016/j.cgh.2024.10.014</doi><orcidid>https://orcid.org/0000-0002-4266-6076</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-3565 |
| ispartof | Clinical gastroenterology and hepatology, 2024-11 |
| issn | 1542-3565 1542-7714 1542-7714 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3129681226 |
| source | Elsevier ScienceDirect Journals |
| subjects | Controlled Attenuation Parameter Liver Stiffness Measurement Metabolic Dysfunction–Associated Steatotic Liver Disease Significant Fibrosis |
| title | Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A31%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20Candidates%20for%20MASLD%20Treatment%20With%20Indeterminate%20Vibration-Controlled%20Transient%20Elastography&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Marti-Aguado,%20David&rft.date=2024-11-16&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2024.10.014&rft_dat=%3Cproquest_cross%3E3129681226%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3129681226&rft_id=info:pmid/39551253&rft_els_id=S1542356524010371&rfr_iscdi=true |